Sarcoma News

The FDA granted priority review designation to larotrectinib for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors harboring an NTRK gene fusion.

Cancer deaths continue to decline among men, women and children in the United States, according to the Annual Report to the Nation on the Status of Cancer.

Larotrectinib showed antitumor activity among infants and children with tropomyosin receptor kinases, or TRK, fusion-positive cancers, according to results of a phase 1 dose-escalation study.

The FDA granted orphan drug designation to the novel cancer vaccine BN-Brachyury for the treatment of chordoma, according to the agent’s manufacturer.

The FDA placed a partial clinical hold on all clinical trials designed to evaluate tazemetostat, according to the drug’s manufacturer.

CHICAGO — Crizotinib induced partial or complete tumor shrinkage among half of patients with inoperable, advanced or metastatic ALK-positive inflammatory myofibroblastic tumor, according to results of the phase 2 EORTC 90101 CREATE trial presented at American Association for Cancer Research Annual Meeting.

An estimated 36 million people worldwide are living with HIV.

James C. Wittig, MD, will receive the Sarcoma Foundation of America’s Nobility in Science Award.

Pediatric patients with solid tumors may have poor-quality T cells compared with patients with leukemia, and certain prior chemotherapies significantly affected the ability of T cells to become effective chimeric antigen receptor T cells, according to a study scheduled for presentation at American Association for Cancer Research Annual Meeting.

NEW ORLEANS — Black patients with soft tissue sarcoma of the extremities are more likely to have amputation, larger tumors, poorer resources and poorer survival than white patients and patients of other races, according to research presented at the American Academy of Orthopaedic Surgeons Annual Meeting.